Kolenko and his colleagues have reported that the decline of Zn in tumor tissues and serum of patients with prostate carcinoma, as well as decreased expression of SLC39A1, 2, and 3 has been detected. This evidence concerns the gene SLC39A1 and prostate carcinoma.